AWS deployed GraphRAG technology in pharmaceutical research environments and reduced drug development cycles by 87 percent. The system integrates previously siloed proprietary databases into a unified knowledge graph that researchers can query directly.

Pharmaceutical companies historically spent over six months in initial data gathering and screening phases per iteration, with only a five percent success rate. The GraphRAG approach consolidates fragmented data sources, eliminating redundant searches across multiple systems. Researchers now access integrated information in a single queryable interface, cutting the time spent on preliminary research substantially.

GraphRAG, built on graph database architecture combined with retrieval-augmented generation, maps relationships between data points. In drug research, this means connecting molecular structures, clinical trial results, existing compounds, and research papers in a machine-readable knowledge graph. Queries that previously required manual cross-referencing across different databases now execute automatically.

The 87 percent reduction translates directly to faster candidate screening. A process that consumed six months can now complete in roughly three weeks. Faster iteration cycles mean pharmaceutical teams test more hypotheses in the same timeframe, increasing the probability of discovering viable drug candidates.

AWS built this deployment using its own cloud infrastructure and RAG tools. The company positioned GraphRAG as solving a specific enterprise problem: data silos that waste researcher time and delay critical work. Pharmaceutical firms generate enormous volumes of structured and unstructured data across labs, clinical trials, and published research. Without unified access, teams repeat searches and miss connections between datasets.

Success rates improved beyond cycle time reductions. The unified knowledge graph surfaces relationships that siloed data hides. Researchers spot compound interactions, similar trial failures, or relevant prior work faster. The system learns from query patterns, improving relevance over time.

AWS has not disclosed which pharmaceutical companies deployed this system or specific drug candidates affected. The 87 percent figure applies to the initial research phases, not full development timelines